一、运营数据 1．主营业务分行业情况 单位：元 2．主营业务分类情况 单位：元 证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2025-037 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 2025 年三季度主要运营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | | | | 营业收入 | | 毛利率 | | --- | --- | --- | --- | --- | --- | --- | | 分产品 | 营业收入 | 营业成本 | 毛利率 | 比上年同 | 营业成本 比上年同 | 比上年 同期增 | | | | | （%） | 期增减 | | | | | | | | （%） | 期增减（%） | 减百分 | | | | | | | | 点 | | 抗肿瘤药 系列 | 387,676,903.77 | 47,684,697.25 | 87.70 | -5.14 | 3.73 | -1.05 | | 皮肤外用抗菌 | 67,252,647.99 | 9, ...

Core Viewpoint - The company Shenqi Pharmaceutical has faced regulatory scrutiny due to financial misconduct, leading to a significant drop in its stock price and raising concerns about its future performance [2][3]. Group 1: Regulatory Issues - Shenqi Pharmaceutical received an administrative regulatory decision from the Shanghai Securities Regulatory Bureau, citing violations related to the misappropriation of sales expenses amounting to 44.838 million yuan through fictitious accounts [2]. - The company has been ordered to rectify its accounting practices, and three executives, including the chairman, received warning letters [2]. - The company claims that the regulatory measures will not affect its normal operations and is currently preparing a rectification report [2]. Group 2: Financial Performance - The company reported a net profit of less than 100 million yuan in recent years, a decline from levels seen before 2019, with revenue continuously decreasing since its peak in 2022 [3][6]. - For the first half of 2025, the company is projected to have revenues of 961 million yuan and a net profit of 32.808 million yuan, representing year-on-year declines of 13.47% and 13.29%, respectively [10]. - The main business segments of the company are pharmaceutical manufacturing and commercial operations, contributing approximately 60% and 40% to revenue, respectively [6]. Group 3: Market Challenges - The company's product line includes older medications, which have faced declining sales due to various healthcare cost control policies, such as payment reforms and price adjustments [6]. - Specific products, such as the sodium cantharidate injections, have seen significant sales in the past but are now categorized closer to auxiliary medications, impacting overall revenue [6].

Core Viewpoint - The company, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., has received administrative regulatory measures from the Shanghai Securities Regulatory Bureau due to irregularities in its accounting practices, specifically related to the handling of accounts receivable [1][2]. Group 1: Regulatory Actions - The Shanghai Securities Regulatory Bureau has mandated corrective measures for the company and issued warning letters to key executives, including the chairman and general manager, for their lack of diligence [1]. - The company is required to submit a written rectification report within 30 days and is expected to improve its accounting practices to prevent future occurrences [2]. Group 2: Financial Impact - In the first half of 2025, the company reported a revenue of 961 million yuan, a decrease of 13.47% year-on-year, and a net profit attributable to shareholders of 32.81 million yuan, down 13.29% year-on-year [2]. Group 3: Company Background - Shanghai Shenqi Pharmaceutical was listed on August 20, 1992, and its main business includes the research, production, and sales of pharmaceuticals, with key products being sodium cantharidate vitamin B6 injection and sodium cantharidate injection [2].

Core Viewpoint - The stock price of Shenqi Pharmaceutical (600613.SH) experienced a significant decline, dropping over 5% after the company was implicated in financial fraud by the Shanghai Securities Regulatory Bureau [2][3]. Financial Misconduct - Shenqi Pharmaceutical was found to have misappropriated sales expenses amounting to 44.83 million yuan through a discontinued "basic drug promotion plan" and fabricated accounts receivable by transferring funds through employee personal accounts [4]. - This fraudulent activity led to the company reversing credit impairment provisions of 44.83 million yuan, resulting in discrepancies in the 2023 annual report [5]. Financial Performance - In 2023, Shenqi Pharmaceutical reported a revenue of 2.341 billion yuan, a year-on-year decrease of 2%, while the net profit attributable to shareholders was 57 million yuan, reflecting a year-on-year increase of 17.41% [7]. - For the first half of 2025, the company achieved a revenue of 961 million yuan, a year-on-year decline of 13.47%, and a net profit of 32.81 million yuan, down 13.29% compared to the previous year [8]. Regulatory Actions - The Shanghai Securities Regulatory Bureau imposed corrective administrative measures on Shenqi Pharmaceutical, issuing warning letters to the then Chairman Zhang Taotao, General Manager Feng Bin, and Chief Financial Officer Chen Zhimian due to the irregularities in accounts receivable handling [7]. - The company has committed to rectifying the issues and submitting a corrective report within the stipulated timeframe to prevent future occurrences [7]. Company Background - Founded in 1983, Shenqi Pharmaceutical specializes in the research, production, and sales of pharmaceuticals, with products covering various therapeutic areas including oncology, respiratory, cardiovascular, and gynecological treatments [7].

Core Insights - The stock price of Shenqi Pharmaceutical (600613.SH) dropped over 7% in intraday trading due to receiving an administrative regulatory decision from the Shanghai Securities Regulatory Bureau regarding financial fraud [1][3] - The company misappropriated sales expenses amounting to 44.8383 million yuan through a discontinued "basic drug promotion plan" and created fictitious accounts receivable, leading to discrepancies in the 2023 annual report [1][3] Financial Performance - In 2023, Shenqi Pharmaceutical reported operating revenue of 2.341 billion yuan, a year-on-year decrease of 2%, while net profit attributable to shareholders was 57.007 million yuan, an increase of 17.41% [3] - For the first half of 2025, the company achieved operating revenue of 961 million yuan, a year-on-year decline of 13.47%, and net profit of 32.8081 million yuan, down 13.29% [4] Regulatory Actions - The Shanghai Securities Regulatory Bureau mandated corrective actions for Shenqi Pharmaceutical, issuing warning letters to the then Chairman Zhang Taotao, General Manager Feng Bin, and Chief Financial Officer Chen Zhimian [3] - The company acknowledged the issue stemmed from improper accounting treatment of accounts receivable and committed to rectifying the situation and submitting a corrective report within the stipulated timeframe [3] Company Background - Founded in 1983, Shenqi Pharmaceutical specializes in the research, production, and sales of pharmaceuticals, with products covering various therapeutic areas including oncology, respiratory, cardiovascular, and gynecological treatments [3]

Core Viewpoint - The company, Shenqi Pharmaceutical, is facing regulatory scrutiny due to financial misconduct, which has led to a significant decline in its financial performance in the first half of 2025. Financial Performance - In the first half of 2025, the company reported a revenue of 961 million yuan, a year-on-year decrease of 13.47% [2] - The net profit attributable to shareholders was 32.81 million yuan, down 13.29% year-on-year [2][3] - The net profit after deducting non-recurring gains and losses was 31.98 million yuan, reflecting a decline of 14.74% year-on-year [2][3] - The net cash flow from operating activities decreased by 61.38%, amounting to 47.47 million yuan, primarily due to reduced sales and slower cash collection [4][3] Business Segments - The pharmaceutical manufacturing segment generated 551 million yuan, a decrease of 17.88%, accounting for 57.35% of total revenue [5] - The pharmaceutical commercial segment reported revenue of 409.74 million yuan, down 6.73%, making up 42.65% of total revenue [5] - The decline in the pharmaceutical manufacturing sector is attributed to falling sales revenue within the industry [4] Regulatory Issues - The company received a corrective order from the Shanghai Securities Regulatory Bureau due to financial misconduct involving the misappropriation of sales expenses totaling 44.84 million yuan [1] - Key executives, including the chairman and general manager, received warning letters for failing to fulfill their responsibilities [1] Market Performance - As of September 26, the company's stock price was 6.39 yuan per share, with a market capitalization of 3.413 billion yuan, indicating stagnant performance throughout the year [5]

Core Viewpoint - The company, Shenqi Pharmaceutical, has been subjected to administrative regulatory measures by the Shanghai Securities Regulatory Bureau due to irregularities in its accounting practices, specifically related to the handling of accounts receivable and the misrepresentation of financial information in its 2023 annual report [1][2]. Group 1: Regulatory Actions - Shenqi Pharmaceutical received a decision from the Shanghai Securities Regulatory Bureau, which includes a directive for corrective measures and warnings issued to key executives for their lack of diligence [1][2]. - The company is required to submit a written rectification report within 30 days and is committed to improving its accounting practices to prevent future occurrences [2]. Group 2: Financial Performance - In the first half of 2025, Shenqi Pharmaceutical reported a decline in both revenue and net profit, with operating income of 961 million yuan, a year-on-year decrease of 13.47%, and a net profit attributable to shareholders of 32.81 million yuan, down 13.29% [3]. - The net cash flow from operating activities decreased by 75.44 million yuan, representing a decline of 61.38%, primarily due to reduced sales and slower collection of receivables [3]. Group 3: Company Overview - Shenqi Pharmaceutical, listed since August 20, 1992, specializes in the research, production, and sales of pharmaceuticals, with key products including anti-tumor drugs and various traditional Chinese medicine formulations [2].

Core Viewpoint - The company reported a significant decline in its main business revenue for the first half of 2025, with a total revenue of 960.85 million yuan, representing a decrease of 149.52 million yuan or 13.47% compared to the previous year [10][12]. Financial Data - The main business revenue for the reporting period was 960.85 million yuan, down from the previous year's figure [10]. - The pharmaceutical manufacturing segment saw a revenue decline of 119.97 million yuan, a decrease of 17.88% [10]. - The pharmaceutical commercial segment experienced a revenue drop of 29.55 million yuan, a decrease of 6.73% [10]. - The total sales revenue from major products was 523.22 million yuan, reflecting a decrease of 123.81 million yuan or 19.14% year-on-year [11]. Regional Performance - Sales revenue by region showed varied performance, with North China experiencing a slight increase of 4.32%, while other regions faced declines: South China down 35.01%, Southwest down 21.33%, Northwest down 20.25%, Northeast down 17.89%, Central China down 12.58%, and East China down 9.53% [12]. - Exports saw a dramatic decline of 88.15% compared to the same period last year [12]. Shareholder Activity - Zhang Ya, a significant shareholder, reduced her holdings by 10,304,700 shares, which accounted for 1.93% of the company's total share capital [3][4].